WindRose recapitalizes Verified Clinical Trials, installs new CEO
What's the deal? WindRose Health InvestorsDealroom has a profile for this one. Try Dealroom → has completed a recapitalization of Verified Clinical TrialsDealroom has a profile for this one. Try Dealroom → (VCT), a provider of subject registry tools that detect duplicate enrolment and protocol violations in clinical research. The New York healthcare private equity firm, which manages roughly $8 billion, did not disclose terms.
The hire: As part of the deal, WindRose is appointing Howard Miller as chief executive officer, with the company's founders, Mitchell Efros, MD, and Kerri Weingard, ANP, remaining active in the business to support its growth strategy.
What's the endgame? VCT runs a secure global database used by sponsors, contract research organisations (CROs), and trial sites to improve patient safety and protect data integrity. WindRose plans to fund further development of the platform and add data and analytics capabilities.
Why now? VCT is positioned to capitalise on rising adoption of its verification solutions. The founders framed the investment as a bid to make VCT's subject verification "the gold standard in clinical trial compliance."
What they're saying: "VCT has developed a truly unique solution that proactively reduces downstream risk for all clinical research constituents," said CJ Burnes, partner at WindRose. Cantor FitzgeraldDealroom has a profile for this one. Try Dealroom → advised VCT on the transaction.
The signal: Private equity continues to target niche healthcare infrastructure — tools that de-risk drug development rather than develop drugs themselves. By backing compliance and data-integrity systems, WindRose is betting that pharmaceutical sponsors will pay to avoid costly trial disruptions.
Read more: PR Newswire
Image credit: Generated with Gemini
